MAPT and Mental deterioration: Not testing for LB positivity when including participants in such AD trials could hamper the ability to detect effects of anti-Aβ or anti-tau treatments on cognitive decline and could potentially be one of several causes for continuous cognitive decline despite complete removal of Aβ from the brain in AD participants23,24.